Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Paradoxical attenuation of autoimmune hepatitis by oral isoniazid in wild-type and N-acetyltransferase-deficient mice.

Metushi IG, Cai P, Vega L, Grant DM, Uetrecht J.

Drug Metab Dispos. 2014 Jun;42(6):963-73. doi: 10.1124/dmd.113.056622. Epub 2014 Mar 12.

PMID:
24623063
[PubMed - indexed for MEDLINE]
2.

Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats.

Metushi IG, Nakagawa T, Uetrecht J.

Chem Res Toxicol. 2012 Nov 19;25(11):2567-76. doi: 10.1021/tx300341r. Epub 2012 Oct 16.

PMID:
23016703
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Role of CYP3A in isoniazid metabolism in vivo.

Liu K, Li F, Lu J, Gao Z, Klaassen CD, Ma X.

Drug Metab Pharmacokinet. 2014;29(2):219-22. Epub 2013 Oct 29.

PMID:
24172716
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression.

Lohse AW, Dienes HP, Meyer zum Büschenfelde KH.

Hepatology. 1998 Jun;27(6):1536-43.

PMID:
9620324
[PubMed - indexed for MEDLINE]
6.

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.

Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, Nicod L, Desmeules J, Hochstrasser D.

Eur J Clin Pharmacol. 2006 Jun;62(6):423-9. Epub 2006 Apr 27.

PMID:
16770646
[PubMed - indexed for MEDLINE]
7.

Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.

Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K.

In Vivo. 2011 Sep-Oct;25(5):803-12.

PMID:
21753138
[PubMed - indexed for MEDLINE]
8.

Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.

Boelsterli UA, Lee KK.

J Gastroenterol Hepatol. 2014 Apr;29(4):678-87. Review.

PMID:
24783247
[PubMed - indexed for MEDLINE]
9.

Relationship between N-acetyltransferase (NAT) activity and liver protoporphyrin level in experimental porphyria.

Watanabe M, Irifune H, Ohgami T, Nonaka S.

J Dermatol. 1996 Apr;23(4):238-42.

PMID:
8935337
[PubMed - indexed for MEDLINE]
10.

Isoniazid-induced liver injury and immune response in mice.

Metushi IG, Uetrecht J.

J Immunotoxicol. 2014 Oct;11(4):383-92. doi: 10.3109/1547691X.2013.860644. Epub 2013 Dec 4.

PMID:
24303880
[PubMed - in process]
11.

Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.

Kubota R, Ohno M, Hasunuma T, Iijima H, Azuma J.

Eur J Clin Pharmacol. 2007 Oct;63(10):927-33. Epub 2007 Jul 31.

PMID:
17665185
[PubMed - indexed for MEDLINE]
12.

Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J.

Int J Tuberc Lung Dis. 2000 Mar;4(3):256-61.

PMID:
10751073
[PubMed - indexed for MEDLINE]
13.

Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.

Sugamori KS, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, Grant DM.

Mol Pharmacol. 2003 Jul;64(1):170-9.

PMID:
12815173
[PubMed - indexed for MEDLINE]
Free Article
14.

Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice.

Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhali GK.

J Hepatol. 2006 Jul;45(1):117-26. Epub 2006 Feb 17.

PMID:
16545483
[PubMed - indexed for MEDLINE]
15.

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.

Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, Okuda Y, Takashima T, Kamimura S, Fujio Y, Kawase I; Pharmacogenetics-based tuberculosis therapy research group.

Eur J Clin Pharmacol. 2013 May;69(5):1091-101. doi: 10.1007/s00228-012-1429-9. Epub 2012 Nov 14.

PMID:
23150149
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol.

Hegde VL, Nagarkatti PS, Nagarkatti M.

PLoS One. 2011 Apr 1;6(4):e18281. doi: 10.1371/journal.pone.0018281.

PMID:
21483776
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid.

Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A.

J Med Genet. 1997 Sep;34(9):758-60.

PMID:
9321764
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.

Metushi IG, Sanders C; Acute Liver Study Group, Lee WM, Uetrecht J.

Hepatology. 2014 Mar;59(3):1084-93. doi: 10.1002/hep.26564. Epub 2014 Jan 27.

PMID:
23775837
[PubMed - indexed for MEDLINE]
19.

Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.

Bozok Cetintaş V, Erer OF, Kosova B, Ozdemir I, Topçuoğlu N, Aktoğu S, Eroğlu Z.

Tuberk Toraks. 2008;56(1):81-6.

PMID:
18330759
[PubMed - indexed for MEDLINE]
20.

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.

Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD.

Hepatology. 2002 Apr;35(4):883-9.

PMID:
11915035
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk